Clinical trials recruiting for HER2-negative Breast Cancer
57
Recruiting trials
37
US states with sites
34
Countries
2%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Fulvestrant | 6 |
| Elacestrant | 5 |
| Famitinib | 4 |
| Letrozole | 4 |
| Anastrozole | 3 |
| Everolimus | 3 |
| Paclitaxel | 3 |
| Pembrolizumab | 3 |
| Ribociclib | 3 |
| SHR-A1811 | 3 |
| SHR-A1921 | 3 |
| 9MW2821 | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 15 |
| Texas | 14 |
| New York | 11 |
| Massachusetts | 10 |
| California | 9 |
| Michigan | 9 |
| Arizona | 8 |
| Colorado | 8 |
| New Jersey | 8 |
| Tennessee | 8 |
| North Carolina | 7 |
| Virginia | 7 |
Top cities
Houston, Texas 11Boston, Massachusetts 10New York, New York 10Nashville, Tennessee 8Chicago, Illinois 6Dallas, Texas 6New Brunswick, New Jersey 6New Haven, Connecticut 6San Antonio, Texas 6Detroit, Michigan 5
Self-screener
Recruiting trials
- A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
- A Study of the TheraBionic P1 Device in Breast Cancer
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Breast Re-irradiation After Second Ipsilateral Lumpectomy
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
- Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
- Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
- Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
- Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
- OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
- Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- PRE-ISPY Phase I/II Oncology Platform Program
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer
- Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
- Reverse HER2-negative Immune Resistant Breast Cancer
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Role of the Immune Environment in Response to Therapy in Breast Cancer
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Sacituzumab Govitecan In TNBC
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
- Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Related conditions
Trials recruiting for HER2-negative Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Metastatic breast cancer 131Advanced Breast Cancer 61Hormone Receptor-Positive Breast Cancer 24Hormone Receptor Positive Tumor 10ER Positive Breast Cancer 12HER2 Negative Breast Carcinoma 15Triple-negative breast cancer 138TNBC - Triple-Negative Breast Cancer 35HER2-positive breast cancer 75
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for HER2-negative Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.